Five Years Follow-up of Neurological Outcome After Minimally Invasive Cardiac Surgery
NCT ID: NCT05330260
Last Updated: 2023-03-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
55 participants
OBSERVATIONAL
2022-03-25
2022-11-07
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Impact of Cerebral Monitoring on Neurologic Outcome in Cardiac Surgery
NCT02006212
The Role of Neuroinflammation on Neurocognitive Outcome in Cardiac Surgery
NCT07200726
Changes in Cerebrovascular Reactivity During Cognitive Activation After Cardiopulmonary Bypass: Relation With Intraoperative Embolic Load and Postoperative Neuropsychological Dysfunctions
NCT00394108
Evaluation of the Ketogenic Diet to Improve Post Operative Cognitive Decline in Cardiac Surgery
NCT06480708
Incidence of Postoperative Cognitive Decline in Patients With Preexisting Cognitive Impairment
NCT07135336
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Literature concerning neurological complications after minimally invasive cardiac surgery (MICS) is scarce. However, this might be of special concern since in MICS, perfusion to the brain is routinely provided via retrograde flow. By consequence, the brain is possibly exposed to aortic atheroma located distal to the cerebral vessels. This is of special interest since embolic phenomena are identified as a trigger for neurologic failure after cardiac surgery. As the practice of MICS is globally expanding, observations on neurologic outcome after MICS are desirable, with screening for short-term as well as long-term complications.
An important reference article concerning late cognitive outcome after CABG surgery prospectively followed a cohort of 102 CABG patients up until five years after surgery. Patients were tested on eight neurocognitive domains at four moments in time: preoperatively, 3 months after surgery, one year after surgery and ultimately five years after surgery. Somewhat surprisingly, at follow-up on one year after surgery, patients performed significantly better at 5/8 cognitive domains without significant worse scores in the remaining domains. The authors note this finding might be attributed to the learning effect. However, on follow-up after five years, a significant decline in several domains was noted, both compared to one year follow-up as to baseline test results. Unfortunately, due to the lack of a (non-surgical) control group, the authors were unable to attribute this finding to CABG surgery itself or to the normal cognitive evolution in this aging, co-morbid population. Therefore, the group performed a nonrandomized longitudinal prospective study between conventional CABG patients, off-pump CABG (OPCAB) patients, nonsurgical coronary artery patients and healthy controls over a six-year follow-up period. They found a larger decline in all three patient groups compared to the healthy control group although none of the groups was substantially worse compared to baseline. As a result, some authors deduct postoperative neurologic decline is more dependent on preoperative patient state rather influenced by procedure-related factors. However, the influence of MICS and retrograde cardiopulmonary bypass (CPB) flow on long-term neurologic decline remains a question.
Between December 2016 and May 2018 the NOMICS trial (Neurologic Outcome after Minimally Invasive Cardiac Surgery) was performed in Jessa Hospitals, Belgium. Three groups were prospectively followed for three months: an endoscopic-CABG group (endo-CABG), a PCI (Percutaneous Coronary Intervention) group and a healthy age and gender matched control group. A battery of neurocognitive tests was performed in all patients and control group to establish the incidence of POCD. By performing these tests again five years after baseline, the investigators will be able to screen for late cognitive decline in a MICS population undergone retrograde arterial CPB flow. Also, because of the presence of two control groups, it might be able to discriminate if the earlier established late decline is typical to the surgical population, to the coronary artery disease (CAD) population and/or normal aging effect.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Endo-CABG
Group that underwent retrograde arterial cardiopulmonary bypass flow.
neurocognitive test battery
Assessment of the incidence of late postoperative cognitive decline (LPOCD)
PCI
Surgical control group
neurocognitive test battery
Assessment of the incidence of late postoperative cognitive decline (LPOCD)
Healthy controls
Non-surgical control group
neurocognitive test battery
Assessment of the incidence of late postoperative cognitive decline (LPOCD)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
neurocognitive test battery
Assessment of the incidence of late postoperative cognitive decline (LPOCD)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Endo-CABG surgery 5 years ago (group 1)
* PCI surgery 5 years ago (group 2)
* Healthy volunteer 5 years ago (group 3)
Exclusion Criteria
* Stroke or POCD
* Symptomatic carotid disease
* Dementia
* Renal dysfunction (GFR \< 30 ml/min)
* Hepatic dysfunction (Aspartate aminotranspferase (SGOT/AST) or Alanine Amino Transpherase (SGPT/ALT) \> 3x normal limits)
* History of drug, medication or alcohol abuse
* Language barrier or inability to communicate
* Physical abnormality that prevents performing the neurocognitive tests
* Surgical revision or presence of intra-operative major cardiac event (endo-CABG)
* Conversion to cardiac surgery of presence of major cardiac event (PCI)
* Simultaneous valve surgery
* Inability to travel to follow-up moment
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Jessa Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Stessel Björn
Principle Investigator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Jessa Hospital
Hasselt, Limburg, Belgium
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
f/2022/012
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.